Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heavy metal containing doai
Reexamination Certificate
2003-10-08
2009-08-11
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heavy metal containing doai
C435S006120, C435S005000, C514S492000, C556S064000, C556S070000
Reexamination Certificate
active
07572828
ABSTRACT:
The invention provides methods and pharmaceutical compositions for inhibiting viral replication, particularly retroviral replication. The methods comprise administration of stibonic acid or diphenyl compounds that disrupt viral nucleocapsid binding to nucleic acids.
REFERENCES:
patent: 4476314 (1984-10-01), Kuriyama et al.
patent: 5041576 (1991-08-01), Wasfi
patent: 6001555 (1999-12-01), Henderson et al.
patent: 6046228 (2000-04-01), Rice et al.
patent: WO 97/44064 (1997-11-01), None
patent: WO 99/65871 (1999-12-01), None
patent: WO 02/062333 (2002-08-01), None
patent: WO 02/096412 (2002-12-01), None
Wafsi and Johnson. The redox potential of some heteropolyanions which are effective antiviral agents. Recent Res. Devel. Inorganic. Chem. 2000; 2:115-129.
Hermans, P. Current review and clinical management of patients with primary HIV-1 infection: limits and perspectives. Biomedecine & Pharmacotherapy. vol. 55, Issue 6, Jul. 2001, pp. 301-307.
Napier, et al. Treatment of ten cases of Kala-azar by sodium acetyl-para-aminophenyl sitbiate (“Stibenyl”). Proc. Roy. Soc. Med. 1922; 15:44-45.
Rice, W., et al., “Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds,”Nature, 1993, vol. 361, pp. 473-475.
Rice, W., et al., “Inhibitors of HIV Nucleocapsid Protein Zinc Fingers as Candidates for the Treatment of AIDS,”Science, 1995, vol. 270, pp. 1194-1197.
Turpin, J., et al., “Synthesis and Biological Properties of Novel Pyridinioalkanoyl Thiolesters (PATE) as Anti-HIV-1 Agents That Target the Viral Nucleocapsid Protein Zinc Fingers,”J. Med. Chem., 1999, vol. 42, pp. 67-86.
Vermeire, K., et al., “Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor,” Expert Opin. Investig. Drugs, 2005, vol. 14, No. 10, pp. 1199-1212.
Yang, Q, et al., “Discovery of Small-Molecule Human Immunodeficiency Virus Type 1 Early Inhibitors That Target the gp120-Binding Domain of CD4,”Journal of Virology, May 2005, vol. 79, No. 10, pp. 6122-6133.
Fossati, C.; “Management of human disease caused by protozoal parasites”; 1978,Clinica Terapeutica, vol. 87, No. 3, 1 page abstract.
Kao, Richard, Y.T. et al.; “A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity”; 2002,PNAS, vol. 99, No. 15, pp. 10066-10071.
Mahato, Shashi B. et al.; “Urea Stibamine: An Improved Method of Preparation and Its Antileishmanial Activity”; 1987,Biochemical Medicine and Metabolic Biology, vol. 38, pp. 47-56.
Wasfi, Sadiq H. et al.; “The redox potentials of some heteropolyanions which are effective antiviral agents”; 2000,Recent Res. Devel. Inorganic Chem., vol. 2, pp. 115-129.
Berenguer, Juan, et al., “Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV),”Annals. of Internal Medicine(1989) 111: 129-132.
Laguna, Fernando, et al., “Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B,”AIDS(1999) 13(9):1063-1069.
Lopez-Velez, Rogelio, et al., “Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus andleishmaniain an area of Madrid, Spain,”Am J. Trop. Med. Hyg. (1998) 58(4): 436-443.
Montalban, C., et al., “Visceral leishmaniasis in patients infected with human immunodeficiency virus,”Journal of Infection(1990) 21: 261-270.
Crise Bruce
Currens Michael
Fisher Robert
Henderson Louis E.
Rein Alan
Mosher Mary E
Snyder Stuart W
The United States of America as represented by the Secretary of
Townsend and Townsend / and Crew LLP
LandOfFree
Identification of anti-HIV compounds inhibiting virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification of anti-HIV compounds inhibiting virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of anti-HIV compounds inhibiting virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4135771